Effects of USP Methylene Blue on Cognitive and fMRI Brain Activity (2013)

Government Record · The University of Texas Health Science Center at San Antonio · August 2013

The University of Texas Health Science Center at San Antonio, 2013-08: Early-phase single-dose trial of 280 mg oral USP methylene blue versus placebo in 36 healthy adults, testing memory, reaction time and fMRI response; completed in 2016 with no results posted.

The purpose of the study is to evaluate whether low-dose USP methylene blue (MB) will: i) improve short-term memory retention in a delayed match-to-sample task

registry record

The University of Texas Health Science Center at San Antonio, 2013-08: Early-phase single-dose trial of 280 mg oral USP methylene blue versus placebo in 36 healthy adults, testing memory, reaction time and fMRI response; completed in 2016 with no results posted. Record field transcription from the registry entry (labelled a record field, confidence MEDIUM). Interventional, randomised, double-blind, single-dose. N=36 actual. Country: USA. Dose: methylene blue (USP grade, 280 mg oral), single administration. Comparator: oral placebo. Sponsor: University of Texas Health Science Center at San Antonio; funder not stated in the record. No results were posted on the registry (hasResults false). Per the run rules a registered trial with no results posted is PARTLY SUPPORTS. Registry status: COMPLETED. No direct PDF exists for a registry record; source_url is the canonical study page. Also filed as MTK-03 (claims C1, C8).